April 16, 2004
Sales of Fuzeon have been slower than many industry analysts expected. The drug has encountered resistance from doctors and patients because of its high cost and injection delivery method. The drug costs about $20,000 per patient per year (Kaiser Daily HIV/AIDS Report, 2/5). Roche says that the high cost of Fuzeon is attributable to its complex manufacturing process, which takes about six months and requires 44 different raw materials and more than 100 manufacturing steps, according to the AP/Newsday (AP/Long Island Newsday, 4/15). To increase demand for the drug, Trimeris said it is working on a new formula for Fuzeon that would reduce injections from twice daily to once per week or even less frequently, the News & Observer reports. Sharon Seiler, an industry analyst who tracks Trimeris, said that reducing the complicated administration of Fuzeon "could only help" (Raleigh News & Observer, 4/15).
Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2004 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.